LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RARE
Ultragenyx Pharmaceutical Inc.
There isn't enough reported data to score RARE yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RARE's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RARE PE Valuation
RARE has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 9.8x next year's earnings.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RARE to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RARE on earnings quality, reporting a profit while its opponent remains loss making.
RARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.67 | — |
| Q3 2026 | -$5.18 | +$0.71 |
| Q2 2026 | -$5.83 | -$0.35 |
| Q1 2026 | -$6.10 | -$0.27 |
| Q4 2025 | -$5.83 | +$0.46 |
| Q3 2025 | -$5.89 | +$0.50 |
| Q2 2025 | -$5.48 | +$1.74 |
| Q1 2025 | -$5.83 | +$2.12 |
| Q4 2024 | -$6.29 | +$1.96 |
RARE is still losing money, but less than at its worst: $5.18 per share over the past year, against $10.26 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RARE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RARE on profitability, with a higher operating margin.
RARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $173M | +8.2% |
| Q2 2026 | $214M | +29% |
| Q1 2026 | $136M | -2.4% |
| Q4 2025 | $207.3M | +26% |
| Q3 2025 | $159.9M | +15% |
| Q2 2025 | $166.5M | +13% |
| Q1 2025 | $139.3M | +28% |
| Q4 2024 | $164.9M | +29% |
RARE's revenue is growing: $173M last quarter, up 8.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +43 points |
| Q2 2026 | -35% | +30 points |
| Q1 2026 | -124% | -22 points |
| Q4 2025 | -55% | +20 points |
| Q3 2025 | -107% | -12 points |
| Q2 2025 | -65% | +14 points |
| Q1 2025 | -103% | +49 points |
| Q4 2024 | -74% | +22 points |
RARE's operating margin was −64% last quarter, up 43 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
RARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$45M | +$47.7M |
| Q2 2026 | -$98M | +$12.7M |
| Q1 2026 | -$198M | -$30.2M |
| Q4 2025 | -$100.8M | -$20.6M |
| Q3 2025 | -$92.7M | -$24.1M |
| Q2 2025 | -$110.7M | -$31.8M |
| Q1 2025 | -$167.8M | +$26.1M |
| Q4 2024 | -$80.2M | +$5.3M |
RARE has burned cash in almost every quarter: −$442M over the past year, against −$451M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +200K shares |
| 1 year | +2.3% | +2.3M shares |
| 3 years | +42% | +30.4M shares |
| 5 years | +50% | +34.2M shares |
| Available history | +80% | +45.5M shares |
RARE has 102M diluted shares, up 2.3% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RARE Net Leverage
RARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 20.3 | Neutral |
RARE's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RARE PE vs Healthcare Sector
RARE has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RARE on trend strength, trading above more of its moving averages.
RARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 5.6% above |
| 20 week MA | $21.0 | 22% below |
| 50 week MA | $23.4 | 31% below |
| 100 week MA | $29.5 | 45% below |
| 200 week MA | $37.2 | 56% below |
RARE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 56% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RARE on returns for 2026, with the stronger performance.
RARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.4 | $172.9 | +298% |
| 2021 | $172.9 | $84.7 | -51% |
| 2022 | $84.7 | $43.5 | -49% |
| 2023 | $43.5 | $47.8 | +9.9% |
| 2024 | $47.8 | $43.4 | -9.2% |
| 2025 | $43.4 | $34.2 | -21% |
| 2026 YTD | $34.2 | $16.3 | -52% |
RARE's yearly returns have swung widely, from +298% in 2020 to −51% in 2021. It's down 52% so far in 2026.